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The immunogenicity of a hall" (51~9) and a full (10~19) dosage of recombinant DNA 
yeast-derived hepatitis B vaccine (HB-Vax-DNA) in healthy neonates was assessed in 
order to compare two candidate dosages of vaccine. After randomization 174 newborns 
o/" HBsAy-negative mothers entered the study. Neonates received four doses of either 10 
or 5 I~ 9 hepatitis B vaccine, according to the DTP-polio immunization schedule at months 
3, 4, 5 and 11. No serious adverse reactions were observed; 15.5% of vaccinated newborns 
suffered mild transient local symptoms. The vaccine was highly immunogenic rrespective 
of dosage of vaccine; all infants developed anti-HBs levels >>. 10 IU 1- I, 99% >>- 100 IU l- 1 
A dosage of 10 ~tg hepatitis B vaccine produced higher antibody levels than 5 t~g hepatitis 
B vaccine after prhnarv vaccination (first three doses) but not after booster vaccination 
(fourth dose) (p = 0.06 and O. 75, respectively). Either vaccine dosage can be recommended 
for incorporation in the Expanded Programme on Immunization i  the Netherlands. 
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The WHO strategy for the control of hepatitis B virus 
(HBV) infection and its sequelae, chronic hepatitis, 
cirrhosis and hepatocellular carcinoma, is mass vaccin- 
ation of infants within the framework of the WHO 
Expanded Programme on Immunization (EPI) 1. In 1982 
plasma-derived hepatitis B vaccine was licensed in The 
Netherlands and a vaccination programme to determine 
an effective and practical immunization schedule for the 
prevention of hepatitis B in neonates of HBsAg positive 
mothers was initiated 2. More than 95% of infants 
developed protective levels of anti-HBs after passive- 
active immunization 2. The most effective and immuno- 
genic schedule was achieved with four adult doses of 
vaccine (10/ag HB-Vax-DNA, Merck Sharp & Dohme 
(MSD), Westpoint, USA), starting at 3 months of age 
concomitant with DTP-polio immunization 2'3. Higher 
antibody levels were obtained after administration of 
three adult doses of 10/~g HB-Vax-DNA (GMT anti-HBs 
at month 12:1236 IU 1-1) than after three infant doses 
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of 5~tg HB-Vax-DNA (GMT anti-HBs at month 12: 
510 IU 1- 1), both starting directly after birth 3. Although 
an anti-HBs level >/10 IU i- 1 is assumed to be protective 
against HBV 4, an adequate response to a course of 
vaccine is generally considered to be an anti-HBs level 
/>100IUI-t which will result in longer lasting 
immunity 5. HB-Vax-DNA recombinant hepatitis B 
vaccine was licensed in the Netherlands in 1987. Until 
now, no studies on the administration ofadult and infant 
doses of HB-Vax-DNA recombinant hepatitis B vaccine, 
administered at months 3, 4, 5 and 11 to neonates of 
HBsAg-negative mothers, have been performed. 
METHODS 
Subjects and randomization 
All pregnant women attending the prenatal clinio of 
the University Hospital Dijkzigt, Rotterdam, the 
Netherlands, were screened at their first visit for the 
presence of HBsAg, in addition to the routine 
determination fblood group/rhesus factor and screening 
for syphilis. HBsAg-negative mothers were informed 
about the current hepatitis B immunization programme. 
Informed consent was obtained from the mother for the 
participation of her infant. Country of birth and age of 
the mother, gestational age, birthweight and sex of the 
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child were registered on the parturition form. To be 
accepted into the study, newborns had to weigh at least 
2000 g at birth and have a 5-minute Apgar score of 7 or 
higher. In total, 214 newborns were randomized into 
groups 1 and 2, according to Peto et al. 6. Forty children 
were not included in the study for the following reasons: 
secondary refusal of the parents (n = 30), birthweight less 
than 2000g (n=4), Apgar score less than 7 (n=5), 
perinatal death (n = 1). As a result, 86 neonates of group 
I and 88 of group 2 entered the study (intention to treat). 
Vaccine and vaccination schemes 
The ad antigenic recombinant DNA yeast-derived 
hepatitis B vaccine was provided by Merck Sharp & 
Dohme (10/zg and 5/~g HB-Vax-DNA, Westpoint, USA); 
I0 pg HBsAg were contained in 1.0 ml, 5 pg HBsAg in 
0.5 ml, both in single-dose vials (lot numbers 496750P, 
557860P, 5806990S, 609540S, 651450S for 10pg 
HB-Vax-DNA and 460201N, 460202N, 088011CH-B, 
580700S, 623040S,676710T for 5/zg HB-Vax-DNA). The 
production, quality control and physicochemical charac- 
teristics of HB-Vax-DNA have been described elsewhere 7. 
The vaccine, stored at 2-8°C, was administered into the 
quadriceps muscle by a physician. Parents were asked to 
record any local (soreness, redness, swelling) or systemic 
(fever >37.5°C, gastrointestinal symptoms) symptoms 
over 3 days following each injection of vaccine. 
Concomitant side-effects known to be due to DTP-polio 
immunization given at the same time were excluded from 
analysis. The 86 neonates of group 1 received four doses 
of 10 pg vaccine and 88 neonates of group 2 received four 
doses of 5 pg vaccine. The vaccine was administered to 
both groups at months 3, 4, 5 (primary vaccination) and 
11 (booster vaccination). 
Blood tests and laboratory methods 
Two millilitres of blood were drawn at month 0 
(umbilical cord blood) and months 4, 6, 11 and 12 in 
both groups. HBsAg, anti-HBc and anti-HBs were 
measured by radioimmunoassay (Ausria II, Corab, 
Ausab, Abbott Laboratories, Chicago, IL, USA). 
Anti-HBs is expressed in International units/litre (IU 1- x) 
after comparison with the WHO standard preparation 
(Central Laboratory of the Netherlands Red Cross Blood 
Transfusion Services, Amsterdam, The Netherlands). 
Statistics 
Statistical analysis was applied on two datasets: data 
according to intention-to-treat data and clean data (data 
of all children who entered the study and were vaccinated 
and assessed according to the protocol). Results between 
'intention to treat data' and 'clean data' did not differ. 
The results of analysis of the clean data are presented 
below. Differences in discrete variables were analysed by 
Fisher's exact est and Z 2 test. Continuous variables were 
analysed by the two-sample Wilcoxon rank sum test for 
unpaired observations. The limit for significance was set 
at 0.05. Geometric mean anti-HBs levels (GMTs) are 
expressed in IU 1-i with 95% confidence intervals (CI). 
RESULTS 
From April 1990 to March 1992, 174 infants born of 
HBsAg-negative mothers entered the study and were 
vaccinated according to the protocol. After primary 
de/Canho et al. 
vaccination serum samples were obtained in 73 (85%) 
and 79 (90%) cases in groups 1 and 2, respectively. After 
booster vaccination, 66 (77%) and 77 (88%) samples were 
available. There were no significant differences incountry 
of birth of the mother, median age of the mother, median 
gestational ge, median birthweight, sex of the child and 
number of infants with anti-HBs positivity and anti-HBc 
positivity in cord blood between the two groups (Table 1). 
Passive transfer of maternal antibodies 
Passively acquired anti-HBs positivity rates for cord 
blood were 13% (n=l l )  and 15% (n=13) for groups 1 
and 2, respectively. Anti-HBc positivity rates at birth 
were 12% (n = 10) and 13% (n = 11), respectively. In all 
but one case anti-HBc was negative at month 12 (in one 
case the test result was not available). 
Anti-HBs seroconversion rate 
Figure 1 shows the frequencies of protective levels of 
anti-HBs levels 1 month after primary and booster 
vaccination in the two groups. All infants who received 
10 pg of vaccine (group 1) developed protective anti-HBs 
levels (/> 10 IU 1- 1) after primary vaccination. All infants 
who received 5pg of vaccine (group 2) developed 
anti-HBs levels /> 10 IU 1-1, but in two cases this did not 
occur until after the booster vaccination. As far as 
long-term protection is concerned, 100% of infants in 
group 1 had anti-HBs levels />100IUI-~ after the 
booster vaccination; for group 2 the corresponding 
percentage was 99%; one child had an anti-HBs level 
between 10 and 100 IU 1- i. Ultimately 88% of the infants 
in group 1 had anti-HBs levels /> I000 IU l-1 after the 
booster vaccination i  comparison to 90% of the infants 
in group 2. 
The anti-HBs levels for two children in group 2 were 
1 IUI-~ and 6 IU I - I ,  respectively, after primary 
vaccination. After the booster vaccination these children 
exhibited 64 and 8078 IU 1-1, respectively. 
Table2 lists the anti-HBs levels (GMT) with 95% CI 
(anti-HBs > 0 IU 1- 1) for the two different schedules. The 
GMT anti-HBs, obtained 1 month after primary 
vaccination and after booster vaccination with four doses 
of 10 pg HB-Vax-DNA, were 231 IU 1- ~ and 4119 IU 1- 1, 
Table 1 Distribution of the entry variables according to vaccination 
groups 1 and 2 
Group 
Variable 1 2 p value 
Number of infants (n) 86 88 
Median gestational age (weeks) 40 39 
Median birthweight (g) 3323 3218 
Sex of child (n): 
Male 51 50 
Female 35 38 
Anti-HBs positive (n) 11 13 
Anti-HBc positive (n) 10 11 
Median age of mother (years) 26 29 
Country of birth of mother (n): 
Netherlands 28 23 
Mediterranean 12 17 
Surinam 29 25 
Asian 1 4 
Miscellaneous 16 19 
0.20" 
0.16" 
0.76 ° 
0.83 ° 
1.00 ° 
0.20 a 
0.45 c 
aWilcoxon rank sum test 
bFisher's exact test 
cZ2 test 
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Rgure 1 Percentage of infants with various anti-HBs levels after 
primary and booster vaccination with 10pg and 5pg HB-Vax-DNA 
hepatitis B vaccine administered at 3, 4, 5 and 11 months of age 
Table 2 Immunogenicity 1 month after primary and booster 
vaccinations with 10pg and 5pg HB-Vax-DNA hepatitis B vaccine 
administered at 3, 4, 5 and 11 months 
Anti-HBs 
(>0 IU 1-1) 
Group No. Month (GMT) 95% CI p value 
1 month after primary vaccination 
1 (10 pg) 73 6 231 163-328 0.06 a 
2 (5 pg) 79 6 137 99-190 
1 month after booster vaccination 
1 (10 pg) 66 12 4119 3064-5538 
2 (5 pg) 77 12 3823 3008-4859 
0.75 a 
aWilcoxon test scheme 1 versus 2 
Table 3 
respectively. This tends to be significantly (Wilcoxon test: 
p = 0.06) higher than those found for infants in group 2 
after primary vaccination (GMT anti-HBs: 137 IU 1-1) 
but not (Wilcoxon test: p = 0.75) after booster vaccination 
(GMT anti-HBs: 3823 IU 1-1). 
Anti-HBs levels at month 24 were available for 32 
infants of group 1 (GMT anti-HBs 290 IU l- 1, 95% CI: 
187-449) and 36 infants of group 2 (GMT anti-HBs 
231 IUI -l, 95% CI: 138-386). 
No significant differences in GMT anti-HBs were 
found between boys and girls, presence of passively 
acquired maternal antibodies (anti-HBs, anti-HBc) and 
various countries of birth of the mother (results not 
shown). 
Adverse reactions to vaccine 
No cases of clinical hepatitis or serious ide-effects of 
the vaccine were reported. In 27 cases (15.5%) the parents 
of the vaccinated children reported transient red swelling 
at the site of injection or fever (less than 39°C). No 
significant differences in the number of side-effects 
between infants in group 1 and group 2 were found 
(results not shown). 
DISCUSSION 
The 10pg and 5pg HB-Vax-DNA hepatitis B vaccines 
used in this study were safe and highly immunogenic. No 
serious ide-effects were reported. In 15.5% of the infants 
mild transient local symptoms were present, irrespective 
of the dose of vaccine. This finding is in agreement with 
earlier results 8'9. 
All infants reached anti-HBs levels >/10 IU l-1, 99% 
/>100 IU I- ', after completion of the vaccination 
schedule (Figure 1). In Table3 the results of different 
studies on the immunogenicity of at least three doses of 
recombinant hepatitis B vaccine (MSD) in healthy 
neonates and infants are listed. Although there is 
agreement in the seroconversion rates, the GMT anti- 
HBs differs (median 1694 IU 1-1, range 307-4119 IU 1-1). 
These differences might be explained by differences in 
maternal HBsAg status, vaccine, dosage, schedule, time 
of blood sampling, age and ethnic background of the 
vaccinees. 
In comparison with a full dosage (20 pg) of Engerix-B 
recombinant hepatitis B vaccine (SmithKline Beecham 
Biologicals (SKB)) administered atmonths 3, 4, 5 and I 1 
to neonates of HBsAg-negative mothers ~°, GMT 
Immunogenicity ofat least three doses of hepatitis B recombinant vaccine (HB-Vax-DNA, Merck Sharp & Dohme) in healthy neonates and infants 
Author 
(year of 
publication) 
Age-group GMT anti-HBs 
Dose Scheme No. of (neonate's mother Seroconversion of converters 
(pg HBsAg) in months vaccinees HBsAg +/ - )  rate (%)" (95% CI) 
Lai (1986) TM 
Stevens (1987) 13 
Milne (1988) 9 
Stevens (1990) 20 
Goh (1992) TM 
Canho del 
(present study) 
5 0, 1 and 6 21 Infants 100 (2) 1894 (?) 
Neonates ( + ) 
5 0, 1 and 6 83 Neonates (+) 100 (6) 307 (?) 
10 0, 1 and 6 56 Infants 98 (2) 3246 (2272-46'36) 
5 0, 1 and 6 60 98 (2) 2305 (1638-3158) 
2.5 0, 1 and 6 56 98 (2) 1370 (866-2169) 
5 0, 1, 2 and 6 94 Neonates (+) 96 (3) 509 (?) 
5 0, 1 and 6 31 Infants 100 (3) 1699 (?) 
2.5 0, 1 and 6 30 93 (3) 1689 (?) 
1.25 0, 1 and 6 29 100 (3) 1135 (?) 
0.6 0, 1 and 6 31 95 (3) 1088 (?) 
10 3, 4, 5 and 11 65 Neonates ( - )  100 (1) 4119 (3064-5538) 
5 3, 4, 5 and 11 71 Neonates ( - )  100 (1) 3823 (3008-4859) 
8Months after completion of vaccination scheme are given in parentheses 
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anti-HBs at months 12 and 24 were 20768 IUI -~ and 
2957 IU 1- 1, respectively, five and ten times higher than 
those obtained with 10pg HB-Vax-DNA in the present 
study. The seroconversion rate for 20pg Engerix-B 
recombinant vaccine (SKB) was the same as that for 10 pg 
HB-Vax-DNA recombinant vaccine (MSD), both being 
100% 1°. In another study four doses of 10~g Engerix-B 
resulted in GMT anti-HBs of 2565 IU l- ~ 1 month after 
the fourth dose, which is 1.5 times lower than in the 
present study; the seroconversion rate was 97.1% 11 
Our previous tudy 2with 10 pg plasma vaccine (MSD), 
administered at months 3, 4, 5 and ll, showed that 
plasma vaccine gives a significantly higher (Wilcoxon 
rank-sum test p = 0.0001) anti-HBs response (n = 99, peak 
level at month 12:13427IU1 -~) than 5 and 10pg of the 
recombinant vaccine evaluated in the present study 
(n=143, peak level groups 1 and 2 at month 12: 
3957 IU 1-1). This finding is in agreement with previous 
studies 12"13. The proportional decline in anti-HBs 
between 12 and 24 months was not significantly different 
(Wilcoxon rank-sum test p=0.3572) between plasma 
vaccine (91%, 95% CI: 21-98) and recombinant vaccine 
(91%, 95% CI: 71-98). This is in agreement with the 
study of Jilg eta/. ~4, who found a 90% reduction in 
anti-HBs, 12 months after the last vaccination with 20 pg 
and 5pg plasma vaccine. However, more long-term 
immunogenicity studies on recombinant hepatitis B 
vaccine are needed to determine whether the decline of 
antibodies resembles that for plasma hepatitis B vaccine. 
The recommended dosage of vaccine for neonates i
ambiguous; Dutch authorities advise a full dosage of 
10 pg HB-Vax-DNA~5; the US Immunization Advisory 
Committee recommends half this standard adult dosage, 
5pg 16. 
Recently, 2 pg and 2.5/ag doses of HB-Vax-DNA were 
recommended for the national childhood immunization 
programme because no significant differences in sero- 
conversion rates could be found between 2.5, 5 and 10pg 
HB-Vax-DNA, administered at months 0, 1 and 6 to 
anti-HBs negative infants, after completion of the 
vaccination schedule ~8. Much lower dosages of 0.6pg 
and 1.25 pg HB-Vax-DNA were even as immunogenic 
as 2.5 pg, but not before month 9 TM. We found that 5pg 
HB-Vax-DNA builds up a lower anti-HBs level than 
10pg HB-Vax-DNA after primary vaccination but that 
difference disappears after the booster vaccination. 
The conclusion isthat lower dosages of vaccine require 
more time to build up the same immunogenicity. For 
universal vaccination of infants of HBsAg-negative 
mothers the rapidity of acquiring the required immuno- 
genicity is less important han for infants of HBsAg- 
positive mothers, who are at greatest risk for becoming 
chronic carriers of HBV. It appears that health 
authorities must opt for that vaccine dosage that will 
satisfy the task they set up. 
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